18h
GlobalData on MSNInceptor Bio doses first subject in trial of IB-T101 for renal cell carcinomaUS-based biotechnology company Inceptor Bio has dosed the first subject in the investigator-initiated trial of its lead ...
Inceptor Bio, a clinical-stage biotechnology company pioneering next-generation cell therapies, today announced that the first patient has been dosed in the clinical trial of IB-T101, the company's ...
Feb. 21, 2025 — A hybrid microscope allows scientists to simultaneously image the full 3D orientation and position of an ensemble of molecules, such as labeled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results